secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longevity Health Holdings, Inc. (XAGE)
CIK:        0001842939
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001193125-23-200597
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carmell Corp to acquire Axolotl Biologix for up to $140M; Axolotl TTM rev $50M, EBITDA $5M
--------------------------------------------------------------------------------

- Axolotl had unaudited TTM revenue ~$50M and TTM EBITDA ~$5M as of June 30, 2023.
- Initial consideration: $8M cash + $57M in CTCX stock ($65M total), plus up to $75M in milestone payments.
- Axolotl's human amnion allografts are FDA-compliant; two products added to CMS Part B pricing in Q2 2023.
- Transaction expected to close in Q3 2023; Axolotl shareholders subject to 12-month lock-up.
- Company changes name to Carmell Corporation; Axolotl CEO Josh Sandberg becomes Strategic Advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/0001193125-23-200597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/d525835d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-200597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer